27748842|t|Downregulation of ZEB2-AS1 decreased tumor growth and metastasis in hepatocellular carcinoma
27748842|a|Hepatocellular carcinoma (HCC) remains one of the most common types of cancer worldwide and prognosis remains poor. Previous studies have suggested that long non‑coding RNAs (lncRNAs) may be key regulators of tumor development and progression in HCC. It has been determined that 61‑72% of transcribed regions contain lncRNAs in the antisense orientation (aslncRNAs). However, the function of aslncRNAs in HCC remains to be elucidated. The present study investigated the function of the aslncRNA zinc finger E‑box binding homeobox 2 antisense RNA 1 (ZEB2‑AS1) in 40 HCC tissues and 5 different human HCC cell lines using reverse transcription‑quantitative polymerase chain reaction. Additionally, the expression levels of ZEB2‑AS1 were downregulated by transfection of small interfering RNAs (siRNAs) to determine whether ZEB2‑AS1 is capable of affecting cell proliferation, invasion and metastasis by regulating ZEB2, vimentin, fibronectin, E‑cadherin and N‑cadherin expression levels. The results of the present study demonstrated that the expression levels of ZEB2‑AS1 were greater in HCC tissues when compared with the adjacent normal tissues. Furthermore, ZEB2‑AS1 expression was significantly associated with the size of the primary tumor, intrahepatic metastasis and tumor-node-metastasis stage. The Kaplan‑Meier survival curves suggested that patients with high ZEB2‑AS1 expression levels experienced the lowest overall and recurrence‑free survival rates compared with those that had low expression levels. In addition, the current study demonstrated that the downregulation of ZEB2‑AS1 was associated with decreased tumor growth and metastasis in HCC by the regulation of the expression levels of epithelial mesenchymal transition - induced markers. In conclusion, lncRNA ZEB2‑AS1 may be used as a valuable biomarker in patients with HCC.
27748842	0	14	Downregulation	T044	C0013081
27748842	18	26	ZEB2-AS1	T028	C2829215
27748842	27	36	decreased	T081	C0205216
27748842	37	49	tumor growth	T191	C0598934
27748842	54	64	metastasis	T191	C0027627
27748842	68	92	hepatocellular carcinoma	T191	C2239176
27748842	93	117	Hepatocellular carcinoma	T191	C2239176
27748842	119	122	HCC	T191	C2239176
27748842	164	170	cancer	T191	C0006826
27748842	185	207	prognosis remains poor	T033	C0278252
27748842	246	266	long non‑coding RNAs	T114,T123	C3494264
27748842	268	275	lncRNAs	T114,T123	C3494264
27748842	288	298	regulators	T077	C1704735
27748842	302	307	tumor	T191	C0027651
27748842	308	319	development	T169	C1527148
27748842	324	335	progression	T191	C0178874
27748842	339	342	HCC	T191	C2239176
27748842	382	393	transcribed	T045	C0040649
27748842	394	401	regions	T082	C0205147
27748842	410	417	lncRNAs	T114,T123	C3494264
27748842	425	446	antisense orientation	T169	C1879714
27748842	448	457	aslncRNAs	T114,T123	C3494264
27748842	473	481	function	T169	C0542341
27748842	485	494	aslncRNAs	T114,T123	C3494264
27748842	498	501	HCC	T191	C2239176
27748842	546	558	investigated	T169	C1292732
27748842	563	571	function	T169	C0542341
27748842	579	587	aslncRNA	T114,T123	C3494264
27748842	588	640	zinc finger E‑box binding homeobox 2 antisense RNA 1	T028	C2829215
27748842	642	650	ZEB2‑AS1	T028	C2829215
27748842	658	661	HCC	T191	C2239176
27748842	662	669	tissues	T024	C0475358
27748842	686	691	human	T016	C0086418
27748842	692	695	HCC	T191	C2239176
27748842	696	706	cell lines	T025	C0085983
27748842	713	773	reverse transcription‑quantitative polymerase chain reaction	T063	C1514628
27748842	793	810	expression levels	T081	C3244092
27748842	814	822	ZEB2‑AS1	T028	C2829215
27748842	828	841	downregulated	T044	C0013081
27748842	845	857	transfection	T045	C0314641
27748842	861	883	small interfering RNAs	T114,T123	C1099354
27748842	885	891	siRNAs	T114,T123	C1099354
27748842	914	922	ZEB2‑AS1	T028	C2829215
27748842	937	946	affecting	T169	C0392760
27748842	947	965	cell proliferation	T043	C0596290
27748842	967	975	invasion	T046	C2699153
27748842	980	990	metastasis	T191	C0027627
27748842	1005	1009	ZEB2	T116,T123	C1505468
27748842	1011	1019	vimentin	T116,T123	C0042666
27748842	1021	1032	fibronectin	T116,T123	C0016055
27748842	1034	1044	E‑cadherin	T116,T123	C0042172
27748842	1049	1059	N‑cadherin	T116,T123	C0027215
27748842	1060	1077	expression levels	T081	C3244092
27748842	1134	1151	expression levels	T081	C3244092
27748842	1155	1163	ZEB2‑AS1	T028	C2829215
27748842	1169	1176	greater	T081	C1704243
27748842	1180	1183	HCC	T191	C2239176
27748842	1184	1191	tissues	T024	C0475358
27748842	1224	1238	normal tissues	T024	C0040300
27748842	1253	1261	ZEB2‑AS1	T028	C2829215
27748842	1262	1272	expression	T045	C0017262
27748842	1291	1306	associated with	T080	C0332281
27748842	1311	1336	size of the primary tumor	T082	C0475440
27748842	1338	1350	intrahepatic	T082	C1512948
27748842	1351	1361	metastasis	T191	C0027627
27748842	1366	1393	tumor-node-metastasis stage	T185	C1302362
27748842	1399	1427	Kaplan‑Meier survival curves	T081	C1720944
27748842	1443	1451	patients	T101	C0030705
27748842	1462	1470	ZEB2‑AS1	T028	C2829215
27748842	1471	1488	expression levels	T081	C3244092
27748842	1505	1511	lowest	T080	C1708760
27748842	1512	1519	overall	T081	C0038954
27748842	1524	1554	recurrence‑free survival rates	T081	C0392762
27748842	1555	1563	compared	T052	C1707455
27748842	1584	1587	low	T080	C0205251
27748842	1588	1605	expression levels	T081	C3244092
27748842	1660	1674	downregulation	T044	C0013081
27748842	1678	1686	ZEB2‑AS1	T028	C2829215
27748842	1691	1706	associated with	T080	C0332281
27748842	1707	1716	decreased	T081	C0205216
27748842	1717	1729	tumor growth	T191	C0598934
27748842	1734	1744	metastasis	T191	C0027627
27748842	1748	1751	HCC	T191	C2239176
27748842	1777	1794	expression levels	T081	C3244092
27748842	1798	1831	epithelial mesenchymal transition	T043	C1523298
27748842	1834	1841	induced	T169	C0205263
27748842	1842	1849	markers	T201	C0005516
27748842	1866	1872	lncRNA	T114,T123	C3494264
27748842	1873	1881	ZEB2‑AS1	T028	C2829215
27748842	1908	1917	biomarker	T201	C0005516
27748842	1921	1929	patients	T101	C0030705
27748842	1935	1938	HCC	T191	C2239176